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OBJECTIVES The purpose of this study was to evaluate the relationship of baseline pulse pressure and mean
arterial pressure to mortality in patients with left ventricular dysfunction.
BACKGROUND Increased conduit vessel stiffness increases pulse pressure and pulsatile load, potentially
contributing to adverse outcomes in patients with left ventricular dysfunction.
METHODS Pulse and mean arterial pressure were analyzed for their effect on mortality, adjusting for other
modifiers of risk, using Cox proportional hazards regression analysis of data collected from
6,781 patients randomized into the Studies of Left Ventricular Dysfunction trials.
RESULTS Pulse and mean arterial pressure were related positively to each other, age, ejection fraction
and prevalence of diabetes and hypertension and inversely to prior myocardial infarction and
beta-adrenergic blocking agent use. Higher pulse pressure was associated with increased
prevalence of female gender, greater calcium channel blocking agent, digoxin and diuretic use,
lower heart rate and a higher rate of reported smoking history. Higher mean arterial pressure
was associated with higher heart rate, lower calcium channel blocker and digoxin use and
lower New York Heart Association functional class. Over a 61-month follow-up 1,582 deaths
(1,397 cardiovascular) occurred. In a multivariate analysis adjusting for the above covariates
and treatment assignment, higher pulse pressure remained an independent predictor of total
and cardiovascular mortality (total mortality relative risk, 1.05 per 10 mm Hg increment; 95%
confidence interval, 1.01 to 1.10; p 5 0.02). Mean arterial pressure was inversely related to
total and cardiovascular mortality (total mortality relative risk, 0.89; 95% confidence interval,
0.85 to 0.94; p ,0.0001).
CONCLUSIONS One noninvasive blood pressure measurement provides two independent prognostic factors
for survival. Increased conduit vessel stiffness, as assessed by pulse pressure, may contribute to
increased mortality in patients with left ventricular dysfunction, independent of mean arterial
pressure. (J Am Coll Cardiol 1999;33:951–8) © 1999 by the American College of
Cardiology
Common clinical wisdom suggests that reduced pulse pres-
sure is associated with worse outcome in patients with left
ventricular dysfunction and heart failure. However, the
Survival and Ventricular Enlargement (SAVE) investigators
have reported a seemingly paradoxical association between
increased pulse pressure and adverse events after myocardial
infarction in patients with left ventricular dysfunction (1).
These investigators have suggested that increased conduit
vessel stiffness, which may be due to elastin degeneration,
collagen deposition or smooth muscle activation, increases
pulse pressure and pulsatile load on the left ventricle and
may contribute to an adverse outcome in patients with left
ventricular dysfunction. A number of other prognostic
markers have been identified in patients with heart failure,
including New York Heart Association (NYHA) functional
class, etiology, age, exercise performance, neurohumoral
activation and alterations in both right and left ventricular
function, size and shape. Neurohumoral activation is gen-
erally associated with advanced left ventricular dysfunction
and reduced mean arterial pressure. This compensatory
mechanism activates smooth muscle in both conduit and
resistance vessels and serves to maintain mean arterial
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pressure at the expense of increased peripheral vascular
resistance and conduit vessel stiffness (2). Thus, pulse
pressure and mean arterial pressure, calculated from sphyg-
momanometric blood pressure, may provide additional
readily obtainable prognostic information in patients with
heart failure.
The Studies of Left Ventricular Dysfunction (SOLVD)
were designed to evaluate the effects of the angiotensin-
converting enzyme (ACE) inhibitor enalapril in patients
with left ventricular dysfunction (3,4). The patients in this
study were sufficiently well characterized to permit a sys-
tematic examination of the effects of pulse pressure and
mean arterial pressure after correcting for a number of well
known covariates and comorbidities. Furthermore, the
SOLVD trials included a broader spectrum of patients with
more severe impairment of left ventricular function than the
SAVE study, including a substantial number of patients
with symptomatic heart failure. Thus, the specific aims of
the present study were 1) to examine the independent
prognostic information about all cause and cardiovascular
mortality provided by sphygmomanometrically determined
pulse pressure in patients with left ventricular dysfunction,
and 2) to quantify the prognostic effect of mean arterial
pressure in these patients.
METHODS
The SOLVD were a concurrent pair of randomized,
double-blind, placebo-controlled trials designed to deter-
mine whether long-term therapy with the ACE inhibitor
enalapril would improve survival in symptomatic (treatment
trial) and asymptomatic (prevention trial) patients with left
ventricular systolic dysfunction (3,4). Patients #80 years old
who were not already on an ACE inhibitor and who had a
left ventricular ejection fraction #0.35 were randomized to
treatment with either enalapril or placebo. The patients
clinically assessed as symptomatic (n 5 2,569) were fol-
lowed for a mean of 41.1 months, and the asymptomatic
patients (n 5 4,228) were followed for a mean of 37.4
months. For the current analysis, 16 patients did not have a
valid baseline blood pressure at the time of randomization
and were excluded (n 5 6,781). The primary end point of
the studies was total (all cause) mortality. The secondary
end point of cardiovascular death was also evaluated in the
present analysis. Before randomization, patient demo-
graphic information was obtained, and a history and phys-
ical examination were performed. This baseline informa-
tion, including sphygmomanometrically determined arterial
blood pressure just before randomization, is the primary
focus of this study. Pulse pressure was determined by
subtracting the diastolic from the systolic blood pressure,
and mean arterial pressure was calculated by using the
formula: [(systolic blood pressure) 1 (2 3 diastolic blood
pressure)]/3. The relationship between mean arterial pres-
sure, pulse pressure and clinical outcomes was then assessed.
Statistical methods. Mean values for continuous variables
and percentages for dichotomous variables known to affect
pulse pressure or prognosis were displayed by quartiles of
pulse pressure and also by quartiles of mean arterial pressure.
Tests for linear trend across quartiles were performed using
logistic regression for dichotomous variables and simple
regression for continuous variables. Kaplan–Meier survival
curve estimates corrected for age and ejection fraction were
calculated for the four quartiles of pulse pressure and
compared by the log-rank test. Cox proportional hazards
regression analyses were performed to estimate the magni-
tude of changes in risk for both total and cardiovascular
mortality conferred by unit changes in pulse pressure and
mean arterial pressure, adjusted for ejection fraction, treat-
ment and other patient characteristics by including these
factors in the regression model. The effect size unit for pulse
pressure and mean arterial pressure was taken as 10 mm Hg.
Separate Cox regression analyses were also performed for
the Treatment and Prevention trials.
RESULTS
Baseline characteristics of the study population. Evalu-
ation by quartiles of pulse pressure, as anticipated, demon-
strated an association between pulse pressure and mean
arterial pressure (Table 1). However, the increase in mean
pressure in higher pulse pressure quartiles was produced
solely by an increase in systolic pressure, as diastolic pressure
remained unchanged across the quartiles. A higher pulse
pressure was associated with more advanced age, higher
prevalences of hypertension and diabetes, female gender and
a lower prevalence of prior myocardial infarction (Table 1).
Although quantitatively small, lower heart rate and higher
ejection fraction were observed in the higher pulse pressure
quartiles. Higher pulse pressure was associated with more
frequent use of calcium channel blocking agents, digoxin
and diuretics and lower use of beta-adrenergic blocking
agents.
Evaluation of quartiles of mean arterial pressure under-
scored the relatively normal blood pressure distribution
curve in this population, with the median value of mean
arterial pressure being 93 mm Hg (Table 2). As opposed to
pulse pressure, the increase across quartiles of mean arterial
pressure was associated with increases in both diastolic and
systolic pressure. The lower quartiles of mean arterial
pressure were associated with lower age and heart rate, lower
prevalence of diabetes and hypertension and a higher
prevalence of prior myocardial infarction. There was greater
Abbreviations and Acronyms
ACE 5 angiotensin-converting enzyme
CI 5 confidence interval
NYHA 5 New York Heart Association
SAVE 5 Survival and Ventricular Enlargement
SOLVD 5 Studies of Left Ventricular Dysfunction
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use of beta-blockers, calcium channel blockers and digitalis
in the lower quartiles. The NYHA functional class was
higher in the low mean arterial pressure group as is also
indicated by a greater proportion of patients in the Treat-
ment compared to the Prevention arm in the lowest mean
arterial pressure group (Table 2).
The effects of pulse pressure were first assessed in a Cox
model that adjusted for mean arterial pressure to evaluate
Table 1. Patient Characteristics by Quartiles of Pulse Pressure
Quartile of Pulse Pressure First Second Third Fourth p Value
Number 1,752 1,706 1,655 1,668 —
Mean arterial pulse pressure range (mm Hg) 6 to 38 39 to 46 47 to 56 57 to 110 —
Mean pulse pressure (SD) (mm Hg) 32 (5) 42 (2) 51 (2) 67 (9) —
Mean systolic blood pressure (SD) (mm Hg) 109 (10) 119 (10) 129 (10) 144 (13) , 0.0001
Mean diastolic blood pressure (SD) (mm Hg) 77 (9) 77 (9) 78 (10) 77 (11) NS
Average mean arterial pressure (SD) (mm Hg) 88 (9) 91 (9) 95 (10) 100 (11) , 0.0001
Age (SD) (years) 55 (10) 59 (10) 61 (9) 64 (8) , 0.0001
Heart rate (SD) 78 (13) 76 (13) 76 (13) 76 (12) , 0.0001
Mean NYHA functional class (1–4) 1.7 1.7 1.7 1.7 NS
Ejection fraction (SD) 26 (7) 27 (6) 27 (6) 28 (6) , 0.0001
History of smoking (%) 25 24 22 21 0.0015
Gender (% female) 13 12 15 18 , 0.0001
Diabetes (%) 13 17 19 28 , 0.0001
Hypertension (%) 30 34 40 52 , 0.0001
Previous MI (%) 76 79 74 69 , 0.0001
Beta-blocker use (%) 21 18 17 16 ,0.0001
Calcium channel blocker use (%) 31 32 34 37 ,0.0001
Aspirin use (%) 43 50 47 46 NS
Digitalis use (%) 33 29 33 38 ,0.0001
Diuretic use (%) 44 39 40 48 0.007
Percent of patients in treatment arm 39 34 37 41 NS
*p value for test for trend.
MI 5 myocardial infarction; NYHA 5 New York Heart Association.
Table 2. Patient Characteristics by Quartiles of Mean Arterial Pressure
Quartile of Mean Arterial Pressure First Second Third Fourth p Value
Number 1,745 1,470 1,889 1,677 —
Mean arterial pressure range 59 to 86 87 to 93 94 to 100 101 to 149 —
Mean arterial pressure (SD) (mm Hg) 80 (5) 90 (2) 96 (2) 107 (6) —
Systolic blood pressure (SD) (mm Hg) 107 (9) 120 (9) 129 (9) 144 (13) —
Diastolic blood pressure (SD) (mm Hg) 66 (6) 74 (5) 80 (4) 89 (6) —
Pulse pressure (SD) (mm Hg) 41 (11) 45 (13) 49 (13) 56 (14) , 0.0001
Age (SD) (yr) 59 (11) 60 (10) 60 (10) 61 (9) , 0.0001
Heart rate (SD) 75 (13) 76 (13) 77 (13) 79 (12) , 0.0001
NYHA functional class (1–4) 1.72 1.66 1.67 1.62 0.0001
Ejection fraction (SD) 26 (6) 27 (6) 27 (6) 27 (6) , 0.0001
History of smoking (%) 23 23 23 23 NS
Gender (% female) 14 15 14 14 NS
Diabetes (%) 18 19 19 21 0.008
Hypertension (%) 26 33 37 60 , 0.0001
Previous MI (%) 79 76 75 69 , 0.0001
Beta-blocker use (%) 21 18 17 16 , 0.0001
Calcium channel blocker use (%) 35 36 32 30 0.0002
Aspirin use (%) 47 46 48 44 NS
Digitalis use (%) 37 34 32 30 , 0.0001
Diuretic use (%) 45 41 40 45 NS
Percent of patients in treatment arm 41 38 36 36 , 0.0001
*p value for test for trend. Abbreviations as in Table 1.
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the relative effects on total mortality of the pulsatile and
steady-flow components of hemodynamic load. Each
10 mm Hg rise in pulse pressure was associated with an 11%
increase in the risk of total mortality (relative risk 1.11, 95%
confidence interval [CI] 1.07 to 1.15, p , 0.0001) and a
10% increase in the risk of cardiovascular mortality (relative
risk 1.10, 95% CI 1.06 to 1.15, p , 0.0001). Furthermore,
each 10 mm Hg decrease in baseline mean arterial pressure
was associated with a 14% increase in the risk of total
mortality (relative risk 0.86, 95% CI 0.82 to 0.91, p ,
0.0001), with identical risk ratio for cardiovascular mortal-
ity. Higher pulse pressure was associated with a higher event
rate after adjusting for age and ejection fraction (Fig. 1).
To determine whether pulse pressure and mean arterial
pressure provide independent prognostic information, Cox
proportional hazard models were constructed that included
these variables as well as age, heart rate, ejection fraction,
history of smoking, gender, diabetes, hypertension, previous
myocardial infarction, medication use and functional status.
In this more inclusive proportional hazards analysis, pulse
pressure remained independently predictive of total mortal-
ity (Table 3). For each 10 mm Hg increase in pulse pressure
there was a 5% increase in the risk of death. A lower mean
arterial pressure was predictive of increased mortality with
an 11% increase for each 10 mm Hg decrement in baseline
mean arterial pressure. An analysis for cardiovascular mor-
tality provided results essentially identical to those for total
mortality (Table 4). These data demonstrate that the
independent contribution of pulse pressure and mean arte-
rial pressure to the risk of death is a consequence of their
influence on cardiovascular deaths.
Subanalysis of the Treatment and Prevention trials sep-
arately yielded similar results with respect to the prognostic
importance of mean arterial pressure and pulse pressure.
DISCUSSION
Present findings. This analysis demonstrates that a single
determination of blood pressure by sphygmomanometry
provides two powerful, independent predictors of adverse
cardiovascular events in a large population of patients with
left ventricular dysfunction—pulse pressure and mean arte-
rial pressure. Furthermore, the analysis underscores a more
physiologic approach to interpreting blood pressure data in
terms of mean and pulsatile components rather than peak
Figure 1. Survival by quartiles of pulse pressure adjusted for age
and ejection fraction.
Table 3. Cox Proportional Hazards Analysis for All
Cause Mortality
Factor
Risk
Ratio p Value
95% Limits
on Risk Ratio
Pulse pressure (10 mm Hg) 1.05 0.019 1.01 to 1.10
Mean arterial pressure (10
mm Hg)
0.89 , 0.0001 0.85 to 0.94
Age 1.02 , 0.0001 1.01 to 1.03
Heart rate 1.00 NS 0.99 to 1.01
Ejection fraction 0.96 , 0.0001 0.96 to 0.97
NYHA functional class
(per unit increase)
1.36 ,0.0001 1.26 to 1.47
History of smoking 1.08 NS 0.95 to 1.22
Female gender 0.86 0.032 0.74 to 0.99
Diabetes 1.28 , 0.0001 1.14 to 1.44
Hypertension 1.09 NS 0.98 to 1.21
Previous MI 0.98 NS 0.87 to 1.10
Beta-blocker use 0.85 0.058 0.72 to 1.00
Calcium channel blocker use 1.16 0.008 1.04 to 1.29
Aspirin use 0.84 0.002 0.75 to 0.94
Digitalis use 1.38 , 0.0001 1.23 to 1.54
Diuretic use 1.39 , 0.0001 1.23 to 1.57
ACE inhibitor use 0.88 0.009 0.79 to 0.97
ACE 5 angiotensin-converting enzyme; other abbreviations as in Table 1.
Table 4. Cox Proportional Hazards Analysis for
Cardiovascular Mortality
Factor
Risk
Ratio p Value
95% Limits
on Risk Ratio
Pulse pressure (10 mm Hg) 1.05 0.019 1.01 to 1.10
Mean arterial pressure
(10 mm Hg)
0.89 , 0.0001 0.84 to 0.94
Age 1.02 , 0.0001 1.01 to 1.02
Heart rate 1.00 0.075 1.00 to 1.01
Ejection fraction 0.96 , 0.0001 0.95 to 0.97
NYHA functional class
(per unit increase)
1.39 , 0.0001 1.29 to 1.51
History of smoking 1.04 NS 0.91 to 1.18
Female gender 0.86 0.049 0.74 to 1.00
Diabetes 1.29 , 0.0001 1.14 to 1.46
Hypertension 1.08 NS 0.97 to 1.22
Previous MI 1.02 NS 0.90 to 1.15
Beta-blocker use 0.87 NS 0.73 to 1.04
Calcium channel blocker
use
1.17 0.007 1.04 to 1.31
Aspirin use 0.85 0.006 0.76 to 0.95
Digitalis use 1.38 , 0.0001 1.22 to 1.56
Diuretic use 1.40 , 0.0001 1.23 to 1.60
ACE inhibitor use 0.84 0.002 0.76 to 0.94
Abbreviations as in Table 3.
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(systolic) and trough (diastolic) values. The large, well
characterized population studied permitted a quantitative
estimate of the effects of mean arterial and pulse pressure on
outcome after extensive correction for age, gender, smoking,
comorbid disease, medication use and functional class at
randomization. Each 10 mm Hg increase in baseline pulse
pressure was associated with a 5% increase in mortality,
whereas a 10 mm Hg decrease in mean arterial pressure was
associated with an 11% increase in risk. The effects of both
mean arterial and pulse pressure were adjusted for covariates
of pulse pressure and other predictors of outcome in patients
with ventricular dysfunction.
Physiologic considerations. Additional physiologic corre-
lates of increased pulse pressure in these patients may help
to explain the adverse prognostic implications of this simple
measurement. Pulse pressure may increase with increased
stroke volume or rate of ejection. However, although a range
of stroke volume and ejection fraction was likely present, it
seems unlikely that the higher stroke volume or ejection
fraction would have been the explanation for an association
of increased pulse pressure and risk of death. In this
population, the increase in pulse pressure was probably most
often related to increased aortic stiffness. Repetitive cyclical
stress leads to breakdown of elastin with aging and reduces
the compliance of the conduit vessels (5). Other disease
processes including diabetes, hypertension, atherosclerosis
and heart failure (5–10) contribute to conduit vessel stiff-
ening as a result of accelerated elastin breakdown, increased
collagen deposition or increased mass or tone of the smooth
muscle component of the conduit vessel wall. Excess vessel
wall stiffness increases aortic impedance to pulsatile flow,
resulting in an increase in the amplitude of the forward
pressure wave for a given flow wave (11). Since peripheral
resistance is increased in heart failure, a greater percentage
of this already enhanced forward pressure wave is reflected
back toward the heart. This increased reflection coefficient is
a consequence of the worsened impedance mismatch be-
tween the low impedance conduit vessels and the high
impedance resistance vessels. In addition, stiffening of the
arterial wall increases pulse wave velocity, which leads to
premature return of the reflected pressure wave from the
periphery (11). The reflected wave therefore returns to the
proximal aorta in mid-to-late systole, rather than in diastole
and augments pulse pressure and left ventricular load while
simultaneously diminishing diastolic pressure. Such a shift-
ing of the reflected wave from diastole to systole would have
no effect on mean arterial pressure, while producing the
highly unfavorable combination of an increase in myocardial
oxygen demand and a decrease in coronary perfusion pres-
sure. The presence of a late systolic pressure peak is also
associated with impaired ventricular relaxation (12,13) and
left ventricular hypertrophy (14).
Increases in conduit vessel stiffness are not purely struc-
tural. The aorta and other large conduit vessels contain a
significant muscular component in the media, which is
capable of modifying the functional characteristics of the
vessels. Increases in the activity of the sympathetic nervous
system and in levels of intrinsic vasoconstrictors lead to
increased smooth muscle tone in both resistance and con-
duit vessels, resulting in elevated peripheral resistance and
increased large vessel stiffness (2,9,10). Neurohumoral acti-
vation has been shown to portend an unfavorable outcome
in patients with congestive heart failure (15,16). One
component of this adverse association may relate to in-
creases in pulsatile load due to dynamic and potentially
reversible increases in conduit vessel stiffness.
In addition to increasing load on the ventricle, the
increased stiffness indicated by the elevated pulse pressure
might be a nonspecific marker for the presence and/or
severity of atherosclerosis, which may reduce aortic compli-
ance (6). Furthermore, independent of the presence of aortic
atherosclerosis, increased vascular stiffness is associated with
risk factors for coronary artery disease, including diabetes
(8), age (17–19), hypertension (5) and a family history of
coronary disease (20). In the present analysis, a significant
positive relationship was found between pulse pressure and
age, diabetes and hypertension. However, even after adjust-
ing for these associated factors, we still found an indepen-
dent relationship between pulse pressure and adverse car-
diovascular events.
In patients with congestive heart failure, the reduction in
resting cardiac output is associated with a lower mean
arterial pressure. Indeed, lower mean arterial pressure has
been associated with poorer prognosis in patients with
congestive heart failure (21,22), although a quantitative
relationship has not been established previously. We have
shown that lower mean arterial pressure predicted a wors-
ened prognosis in the SOLVD population. This relation-
ship was observed despite the fact that younger age, lower
heart rate, a lower incidence of diabetes and more frequent
use of beta-blockers, as seen in the lower mean arterial
pressure quartiles, each would have predicted a better
prognosis. The reduction in cardiac output causes neurohu-
moral activation as a compensatory mechanism that in-
creases systemic vascular resistance. As noted above, neuro-
humoral activation may have also increased stiffness of the
conduit vessels in these patients. For example, a patient with
a “normal” blood pressure of 120/80 mm Hg has a mean
arterial pressure of 93 mm Hg and a pulse pressure of
40 mm Hg. In contrast, SOLVD patients in the third
quartile for mean arterial pressure had a near normal mean
arterial pressure (96 mm Hg), yet they had an elevated pulse
pressure (49 mm Hg). Thus, the adverse prognosis imparted
by directionally opposite changes in pulse pressure and
mean arterial pressure may in part represent a common
mechanism.
Previous studies of pulsatile load and adverse events.
Few studies have directly evaluated the relationship between
pulse pressure and cardiac events. However, a number of
studies have related left ventricular mass to various measures
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of pulsatile load, including proximal aortic elastance (23),
pulse wave velocity (24), characteristic impedance of the
aorta (25–27), pulse pressure (28), brachial artery compli-
ance (29) and premature arrival of the reflected wave (30).
Because left ventricular mass has been related to adverse
events, it is reasonable to hypothesize that elevated pulse
pressure, an indicator of pulsatile load, might constitute a
cardiovascular risk factor. Indeed, it has recently been shown
that pulse pressure is an independent predictor of total
mortality and recurrent myocardial infarction in patients
with impaired ventricular function after a myocardial infarc-
tion (1). No other studies have specifically addressed the
relationship between pulse pressure and cardiac events in
patients with left ventricular dysfunction. Furthermore, this
is the first prospective analysis that has evaluated the effects
of pulse pressure in a population of patients with left
ventricular dysfunction that includes a significant number of
patients with overt heart failure.
Other major studies have addressed the relationship
between pulse pressure and cardiac events in normal or
hypertensive patient populations. In a prospective study of
healthy adults, the pulsatile component index, a strong
correlate of pulse pressure, was associated with an increased
risk of death from coronary artery disease in women (31). In
a recently published update to this study, with 19.5 years of
follow up in 19,083 men, pulse pressure again proved to be
associated with cardiovascular events after adjusting for age,
cholesterol and tobacco use (32). The relative effects of
diastolic, systolic and pulse pressure on five-year mortality
were evaluated in hypertensive adults in the Hypertension
Detection and Follow-up Program (33). Pulse pressure was
shown to be a significant predictor of total mortality in a
logistic regression model that included age, race, gender,
randomized antihypertensive therapy, diabetes, hypertensive
end-organ damage and smoking. In another prospective
evaluation of hypertensive patients, those in the highest
tertile of pulse pressure before the initiation of therapy
($63 mm Hg) had an increased risk of myocardial infarc-
tion and stroke during an average follow up of five years
(34). Multivariate analysis revealed that pretreatment pulse
pressure was an independent predictor of myocardial infarc-
tion. A follow-up analysis in an expanded patient popula-
tion of treated and untreated hypertensive patients con-
firmed that pulse pressure was the only measure of blood
pressure independently associated with myocardial infarc-
tion after adjustment for other risk factors (35).
Previous studies of mean arterial pressure and outcome.
Many studies have alluded to an association between mean
arterial pressure and an adverse outcome in patients with
varying degrees of heart failure. However, few have con-
trolled for other factors that contribute to an adverse
outcome. In a prospective study of 182 patients with
advanced heart failure, patients who died had a lower
baseline mean arterial pressure, which was associated with
reduced cardiac output and elevated systemic vascular resis-
tance (36). The patients in this study were well character-
ized with respect to other predictors of outcome. However,
a multivariate analysis was not performed. Another prospec-
tive study of 152 patients with NYHA functional class
II–IV heart failure demonstrated a significant relationship
between mean arterial pressure and outcome. Lower mean
arterial pressure was associated with a lower serum sodium
concentration, higher functional class score and larger dia-
stolic left ventricular size. Lower mean arterial pressure
remained an independent predictor of outcome in a stepwise
multivariate analysis, although no estimate of effect size was
given (37).
Clinical implications. Prospective studies that evaluate the
clinical implications of interventions that improve conduit
vessel compliance have not been done. However, agents
such as ACE inhibitors, which have been shown to have a
salutary effect on conduit vessel function, are highly effective
in improving outcome in patients with asymptomatic left
ventricular dysfunction (38) and all stages of congestive
heart failure (3,4,39,40). Clinical studies have confirmed
that abnormalities in conduit vessel function are modifiable
(25,41– 46). Thus, abnormal conduit vessel function,
whether due to increased smooth muscle mass or tone,
increased collagen or diminished elastin appears to be at
least partially responsive to various therapeutic interven-
tions. This provides a rationale for testing therapeutic
agents with a preferential effect on conduit vessel function
and pulse pressure.
Limitations. Our analysis was based on a single blood
pressure measurement and could, therefore, suffer from
regression to the mean. However, this would tend to
obscure, rather than enhance, an important association
between hemodynamic parameters and outcome. Pulse
pressure is an imperfect indicator of conduit vessel stiffness,
and more direct measures are needed for future studies.
Nonetheless, it is difficult to envision how increases in other
potential determinants of pulse pressure, such as peak
ejection rate or stroke volume, would be associated with an
adverse prognosis in patients with left ventricular dysfunc-
tion. It is important to note that this analysis was explor-
atory in nature and was not a prespecified end point of the
SOLVD studies. These findings apply only to patients with
left ventricular dysfunction. As with any risk factor, it is
difficult to apply it to a particular individual rather than to
the entire population. However, our model indicates that
pulse pressure provides independent prognostic informa-
tion.
Conclusions. These data provide strong evidence for asso-
ciations between conduit vessel stiffness, which contributes
to increased pulse pressure, resistance vessel activation,
which accompanies a fall in mean arterial pressure and
adverse cardiovascular events in patients with left ventricular
dysfunction. We speculate that therapies directed at reduc-
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ing pulse pressure may offer potential advantages in the
treatment of congestive heart failure.
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